Nektar Therapeutics (LON:0UNL)
London flag London · Delayed Price · Currency is GBP · Price in USD
0.8357
+0.0053 (0.64%)
At close: Jan 31, 2025

Nektar Therapeutics Revenue

Nektar Therapeutics had revenue of $10.46M USD in the quarter ending March 31, 2025, a decrease of -51.66%. This brings the company's revenue in the last twelve months to $87.25M, down -3.24% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.

Revenue (ttm)
$87.25M
Revenue Growth
-3.24%
P/S Ratio
1.34
Revenue / Employee
$1.43M
Employees
61
Market Cap
90.19M GBP

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202498.43M8.31M9.22%
Dec 31, 202390.12M-1.93M-2.10%
Dec 31, 202292.06M-9.85M-9.67%
Dec 31, 2021101.91M-51.01M-33.36%
Dec 31, 2020152.92M38.30M33.41%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 42.56B
GSK plc 31.53B
Haleon 11.23B
Smith & Nephew 4.64B
ConvaTec Group 1.83B
Hikma Pharmaceuticals 2.50B
HUTCHMED (China) 503.39M
Genus 671.60M
Revenue Rankings